ACoP Contributions from Kyle Baron, Pharm.D., Ph.D.
Accounting For Dose Modifications In Exposure-Response Analyses In Oncology: The Case Example Of Brigimadlin. Jia Kang, Ph.D.; Matthew Wiens, M.A.; James Rogers, Ph.D.; Kyle Baron, Pharm.D., Ph.D.
pmparams: an R Package for Defining and Formatting Parameter Tables in Pharmacometric Modeling. Grace O’Brien, Ph.D.; Eric Anderson, Ph.D.; Michael McDermott, Ph.D.; Kyle Barrett, Kyle T. Baron, Pharm.D., Ph.D.; Timothy Waterhouse, Ph.D.; Seth Green, M.S.; Katherine Kay, Ph.D.
Simulating Dynamic Adaptive Dosing Regimens from PK and PKPD Models Using mrgsolve Kyle Baron, Pharm.D., Ph.D.
Data Gaps, Model Mishaps: Quantifying the Impact of Missing Pharmacometrics Data on Pharmacodynamic Projections. Rena Byrne, Ph.D.; Hillary Husband, Ph.D.; Megan Cala Pane, Ph.D.; Curtis Johnston, Pharm.D.
Reinforcement Learning for Pharmacometrics: A Proof of Concept and Future Directions. Annaliese Wieler, M.S.; Matthew Wiens, M.A.; Samuel P. Callisto, Ph.D.; Megan Cala Pane, Ph.D.; Hillary Husband, Ph.D.
How to Make a Salad? Rethinking Pharmacometric/QSP Model Composition using Open-Source Julia Tools. Ahmed Elmokadem, Ph.D.; Timothy Knab, Ph.D.; Daniel Kirouac, Ph.D.
Symbolic PBPK-PDE Modeling using Open-Source Julia Tools. Ahmed Elmokadem, Ph.D.; Jimena Davis, Ph.D.; Yuezhe Li, Ph.D.; Timothy Knab, Ph.D.; Daniel Kirouac, Ph.D.
Pharmacometric-Pharmacoeconomic Modeling and Simulation in Atopic Dermatitis: Informing Early Drug Development Decisions for a Hypothetical New Therapeutic. Marc R. Gastonguay, Ph.D.; Dan Polhamus, Ph.D. Michelle Johnson, M.B.A.; Eric Anderson, M.S.; Kyle Barrett
Workshop: Workshop: Efficient reproducible Bayesian population PK modeling with NONMEM and Stan/Torsten Gillespie, Ph.D.; Timothy Waterhouse, Ph.D.; Curtis Johnston, Pharm.D.; Seth Green, M.S. 8:00 AM - 5:00 PM MST Location: Mesquite
pmparams: an R Package for Defining and Formatting Parameter Tables in Pharmacometric Modeling. Grace O’Brien, Ph.D.; Eric Anderson, Ph.D.; Michael McDermott, Ph.D.; Kyle Barrett, Kyle T. Baron, Pharm.D., Ph.D.; Timothy Waterhouse, Ph.D.; Seth Green, M.S.; Katherine Kay, Ph.D.
Longitudinal Joint Modeling of Modified Mayo Score and Dropout in Patients with Moderate to Severely Active Ulcerative Colitis. Timothy Waterhouse, Ph.D.; Mike Heathman M.S. (contributing)
The effect of CYP2B6 genotype on the clearance and autoinduction of efavirenz in healthy subjects and the subsequent impact on efavirenz exposure. Mike Heathman, M.S.
Data Gaps, Model Mishaps: Quantifying the Impact of Missing Pharmacometrics Data on Pharmacodynamic Projections. Rena Byrne, Ph.D.; Hillary Husband, Ph.D.; Megan Cala Pane, Ph.D.; Curtis Johnston, Pharm.D.
Reinforcement Learning for Pharmacometrics: A Proof of Concept and Future Directions. Annaliese Wieler, M.S.; Matthew Wiens, M.A.; Samuel P. Callisto, Ph.D.; Megan Cala Pane, Ph.D.; Hillary Husband, Ph.D.
Pharmacometric-Pharmacoeconomic Modeling and Simulation in Atopic Dermatitis: Informing Early Drug Development Decisions for a Hypothetical New Therapeutic. Marc R. Gastonguay, Ph.D.; Dan Polhamus, Ph.D. Michelle Johnson, M.B.A.; Eric Anderson, M.S.; Kyle Barrett
Workshop: Efficient reproducible Bayesian population PK modeling with NONMEM and Stan/Torsten. William Gillespie, Ph.D.; Timothy Waterhouse, Ph.D.; Curtis Johnston, Pharm.D.; Seth Green, M.S. 8:00 AM - 5:00 PM MST Location: Mesquite
Data Gaps, Model Mishaps: Quantifying the Impact of Missing Pharmacometrics Data on Pharmacodynamic Projections. Rena Byrne, Ph.D.; Hillary Husband, Ph.D.; Megan Cala Pane, Ph.D.; Curtis Johnston, Pharm.D.
Losing the Forest: Causal Shapley Values for interpretation of Population-Pharmacometric Models. Matthew Wiens, M.S.; Elias Clark, Ph.D.; Curtis Johnston, Pharm.D.
Accounting For Dose Modifications In Exposure-Response Analyses In Oncology: The Case Example Of Brigimadlin. Jia Kang, Ph.D.; Matthew Wiens, M.A.; James Rogers, Ph.D.; Kyle Baron, Pharm.D., Ph.D.
Vice President of Translational and Systems Pharmacology (TSP)
ACoP Contributions from Daniel Kirouac, Ph.D.
How to Make a Salad? Rethinking Pharmacometric/QSP Model Composition using Open-Source Julia Tools. Ahmed Elmokadem, Ph.D.; Timothy Knab, Ph.D.; Daniel Kirouac, Ph.D.
Quantitative systems pharmacology modeling of loncastuximab tesirine combined with mosunetuzumab and glofitamab helps guide dosing for patients with DLBCL. Yuezhe Li, Ph.D.; Katharina Wilkins, Ph.D.; Tim Knab, Ph.D.; Daniel Kirouac, Ph.D.
Symbolic PBPK-PDE Modeling using Open-Source Julia Tools. Ahmed Elmokadem, Ph.D.; Jimena Davis, Ph.D.; Yuezhe Li, Ph.D.; Timothy Knab, Ph.D.; Daniel Kirouac, Ph.D.
Quantitative systems pharmacology modeling of loncastuximab tesirine combined with mosunetuzumab and glofitamab helps guide dosing for patients with DLBCL. Yuezhe Li, Ph.D.; Katharina Wilkins, Ph.D.; Tim Knab, Ph.D.; Daniel Kirouac, Ph.D.
Symbolic PBPK-PDE Modeling using Open-Source Julia Tools. Ahmed Elmokadem, Ph.D.; Jimena Davis, Ph.D.; Yuezhe Li, Ph.D.; Timothy Knab, Ph.D.; Daniel Kirouac, Ph.D.
pmparams: an R Package for Defining and Formatting Parameter Tables in Pharmacometric Modeling. Grace O’Brien, Ph.D.; Eric Anderson, Ph.D.; Michael McDermott, Ph.D.; Kyle Barrett, Kyle T. Baron, Pharm.D., Ph.D.; Timothy Waterhouse, Ph.D.; Seth Green, M.S.; Katherine Kay, Ph.D.
ACoP Contributions from Matthew M. Riggs, Ph.D., FISoP
Quantitative Systems Pharmacology Modeling of X-linked Hypophosphatemia Disease Pathway Normalization to Predict the Impact of Burosumab Treatment on Serum Biomarkers in Adult and Pediatric Patients Daisuke Takaichi et al with co-author contributions from Kiersten Utsey, Ph.D.; Matthew Riggs, Ph.D., FISoP
Scientific Project Management (SPM) to Enhance Model-Informed Drug Development. Jeannine Fisher, M.S.; William Knebel Pharm.D, Ph.D; Matthew Riggs, FISoP, Ph.D; Bryon Baxter; Uchenna Emechebe, Ph.D; Joseph Pliss, M.B.A.
Workshop: Efficient reproducible Bayesian population PK modeling with NONMEM and Stan/Torsten. William Gillespie, Ph.D.; Timothy Waterhouse, Ph.D.; Curtis Johnston, Pharm.D.; Seth Green, M.S. 8:00 AM - 5:00 PM MST Location: Mesquite
Session: The Practical Bayesian: How Bayesian Methodology is Incorporated into Clinical Drug Development. Co-Speaker: Tim Waterhouse, Ph.D. 1:45 PM - 3:15 PM MST
Session: Hybrid Approaches in Pharmacometric Modeling: Integrating Maximum Likelihood and Bayesian Estimation Speaker: Tim Waterhouse, Ph.D. 1:45 PM - 2:15 PM MST
Gompertz Cure Rate Survival Models with Stan and brms. Todd Yoder, Ph.D.; Andrew Tredennick, Ph.D.; Timothy Waterhouse, Ph.D.
Longitudinal Joint Modeling of Modified Mayo Score and Dropout in Patients with Moderate to Severely Active Ulcerative Colitis. Timothy Waterhouse, Ph.D.; Mike Heathman M.S. (contributing)
pmparams: an R Package for Defining and Formatting Parameter Tables in Pharmacometric Modeling. Grace O’Brien, Ph.D.; Eric Anderson, Ph.D.; Michael McDermott, Ph.D.; Kyle Barrett, Kyle T. Baron, Pharm.D., Ph.D.; Timothy Waterhouse, Ph.D.; Seth Green, M.S.; Katherine Kay, Ph.D.
Reinforcement Learning for Pharmacometrics: A Proof of Concept and Future Directions. Annaliese Wieler, M.S.; Matthew Wiens, M.A.; Samuel P. Callisto, Ph.D.; Megan Cala Pane, Ph.D.; Hillary Husband, Ph.D.
Accounting For Dose Modifications In Exposure-Response Analyses In Oncology: The Case Example Of Brigimadlin. Jia Kang, Ph.D.; Matthew Wiens, M.A.; James Rogers, Ph.D.; Kyle Baron, Pharm.D., Ph.D.
Losing the Forest: Causal Shapley Values for interpretation of Population-Pharmacometric Models. Matthew Wiens, M.S.; Elias Clark, Ph.D.; Curtis Johnston, Pharm.D.
Reinforcement Learning for Pharmacometrics: A Proof of Concept and Future Directions. Annaliese Wieler, M.S.; Matthew Wiens, M.A.; Samuel P. Callisto, Ph.D.; Megan Cala Pane, Ph.D.; Hillary Husband, Ph.D.
Session: Quantitative clinical pharmacology of antibody conjugate development: challenges and opportunities. Speaker: Katharina Wilkins, Ph.D. 1:45 - 3:15 PM MST
Session: Mechanistic QSP modeling for deeper understanding of ADC toxicities and combination effects with immunotherapies. Co-Speaker: Katharina Wilkins, Ph.D. 1:45 - 2:15 PM MST
Quantitative systems pharmacology modeling of loncastuximab tesirine combined with mosunetuzumab and glofitamab helps guide dosing for patients with DLBCL. Yuezhe Li, Ph.D.; Katharina Wilkins, Ph.D.; Tim Knab, Ph.D.; Daniel Kirouac, Ph.D.
.jpg?width=500&height=117&name=metrum_new_logo%20(high_res).jpg "Metrum Research Group")
